PCDHB5 Inhibitors
PCDHB5 inhibitors encompass a variety of chemical compounds that downregulate the activity of PCDHB5 through different mechanisms associated with cellular signaling and adhesion processes. Inhibitors such as those targeting protein kinase C (PKC) and glycogen synthase kinase-3 (GSK-3) interfere with phosphorylation events that are crucial for the function and stability of PCDHB5. For instance, by reducing PKC-mediated phosphorylation, the stability and function of PCDHB5 in cellular adhesion could be compromised. Similarly, selective GSK-3 inhibitors may alter the phosphorylation states of PCDHB5-associated substrates, weakening its cell adhesion and signaling capabilities. Furthermore, compounds that inhibit the MEK/ERK signaling pathway may affect the transcriptional regulation of PCDHB5 or its interaction with other proteins, thereby decreasing its functional activity.
Additional PCDHB5 inhibitors operate by disrupting the dynamics of the actin cytoskeleton and cell shape, which are essential for PCDHB5-mediated cell-cell adhesion and signaling. ROCK inhibitors, for example, can potentially alter PCDHB5's role in these processes. Inhibition of Rac1 activation similarly affects the regulation of actin structures that PCDHB5 helps stabilize. Phosphatidylinositol 3-kinase (PI3K) inhibitors impair Akt signaling, potentially disrupting PCDHB5's trafficking and membrane localization. Additionally, JNK pathway inhibitors could suppress the regulation of PCDHB5 expression or stability. Lastly, interference with β-catenin levels through tankyrase inhibition or γ-secretase inhibition could indirectly reduce PCDHB5's adhesion function, as these processes are closely tied to the regulation and processing of proteins that collaborate with or control PCDHB5 within the cell adhesion framework.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A potent and specific inhibitor of protein kinase C (PKC), which indirectly inhibits PCDHB5 by reducing PKC-mediated phosphorylation that could be crucial for PCDHB5's stabilization and function in cellular adhesion processes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits glycogen synthase kinase-3 (GSK-3), a kinase that may phosphorylate substrates that affect the stability and localization of PCDHB5, thus indirectly reducing PCDHB5-mediated cell adhesion and signaling. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A selective inhibitor of GSK-3, leading to potential alterations in phosphorylation states of molecules that interact with or regulate PCDHB5, thereby decreasing PCDHB5's cellular adhesion functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which subsequently reduces ERK pathway activity. As a result, transcription factors modulating PCDHB5 expression or proteins interacting with PCDHB5 might be affected, leading to reduced PCDHB5 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor which may disrupt actin cytoskeleton dynamics and cell shape changes, potentially affecting PCDHB5's role in cell-cell adhesion and signaling. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Disrupts Rac1 activation, which is involved in the regulation of the actin cytoskeleton. This alteration could indirectly inhibit PCDHB5 by affecting the cellular structures it is involved in stabilizing. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, leading to downstream inhibition of Akt signaling. This could affect the trafficking, localization, or stability of PCDHB5 in the cell membrane. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, reducing the activity of the ERK pathway and potentially impacting the expression or function of PCDHB5 through altered phosphorylation states of associated proteins. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that compromises Akt signaling, which may impact the membrane localization or function of PCDHB5 by altering its interaction with other signaling molecules. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could affect transcription factors or other proteins that regulate the expression or stability of PCDHB5, leading to its functional inhibition. | ||||||